TY  - JOUR
A1  - Straalen, Kelsey R. van
A1  - Tzellos, Thrasyvoulos
A1  - Guillem, Phillipe
A1  - Benhadou, Farida
A1  - Cuenca-Barrales, Carlos
A1  - Daxhele, Mathilde
A1  - Daoud, Mathieu
A1  - Efthymiou, Ourania
A1  - Giamarellos-Bourboulis, Evangelos J.
A1  - Jemec, Gregor B. E.
A1  - Katoulis, Alexandros
A1  - König, Anke
A1  - Lazaridou, Elizabeth
A1  - Marzano, Angelo V.
A1  - Matusiak, Łucas
A1  - Molina-Leyva, Alejandro
A1  - Moltrasio, Chiara
A1  - Pinter, Andreas
A1  - Potenza, Concetta
A1  - Romaní, Jorge
A1  - Saunte, Ditte M.
A1  - Skroza, Nevena
A1  - Stergianou, Dimitra
A1  - Szepietowski, Jacek C.
A1  - Trigoni, Anastasia
A1  - Vilarrasa, Eva
A1  - Zee, Hessel H. van der
T1  - The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study
T2  - Journal of the American Academy of Dermatology
N2  - Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019. Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain. Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.
KW  - acne inversa
KW  - antibiotics
KW  - clindamycin
KW  - doxycycline
KW  - efficacy
KW  - guideline
KW  - minocycline
KW  - outcome
KW  - rifampicin
KW  - tetracycline
KW  - therapy
KW  - treatment
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63089
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-630895
SN  - 1097-6787
VL  - 85.2021
IS  - 2
SP  - 369
EP  - 378
PB  - Elsevier
CY  - Amsterdam [u.a.]
ER  -